But the researchers, funded by the National Institute for Health Research Health Technology Assessment and Cancer Research UK1, caution that guidelines are needed before this type of scan, also called CT colonography (CTC), is used more widely because its ability to detect relatively unimportant findings can result in patients being referred for unnecessary follow-up tests.
In the first of the two trials2, published in the Lancet today, more than 3,800 patients were given either a CTC or a barium enema. The researchers showed that CTC was more effective than barium enema at finding bowel cancers and precancerous polyps.
Professor Steve Halligan, based at UCL and joint-lead researcher, said: “Our trial shows that CTC is more accurate than barium enema. We hope that barium enema will now be phased out in favour of CTC and that NICE will update its guidelines. Although CTC can be performed on standard CT scanners available in practically all NHS hospitals, many do not have radiologists experienced with looking at CTC scans. These radiologists will need training in order to deliver the results we observed in our trials.”
In a second trial3 almost 1,600 patients were given either a CTC or a colonoscopy. Previous studies have shown that these two tests have similar sensitivity for detecting bowel cancer.
Unlike colonoscopy, samples of tissue cannot be taken at CTC and it was not known how many patients needed a follow-up test to either confirm a suspected cancer or to rule out other findings found in the scan. Similarly, it was not known how many patients needed a follow-up test after colonoscopy because the scope could not pass around the bowel.
In patients who had CTC, 30 per cent had a follow-up test compared with only eight per cent who had colonoscopy. Some of the follow-up tests after CTC were necessary because a possible cancer or large polyp had been seen. However, almost a third of follow-up tests were to investigate small polyps that could have been left alone because they are unlikely to develop into cancers.
Professor Wendy Atkin, based at Imperial College London and joint-lead researcher, said: “Understandably hospital doctors are cautious in requesting more tests after CTC. However, CTC detects unimportant findings, so guidelines are needed to help doctors decide who should have a further test. With these in place, we have shown that CTC offers a viable option for people who are not able to or do not wish to undergo a colonoscopy for whatever reason.”
CTC works by taking hundreds of x-ray “slices” through the body which are then processed by a computer to create a ‘virtual’ 3D image of the inside of the bowel, similar to what is seen during colonoscopy. CTC is a less uncomfortable test and, unlike colonoscopy, patients do not need to be sedated.
Professor Jane Wardle, based at UCL, who led studies looking into patient experiences of the three tests, said: “We have shown that people prefer CTC to both barium enema and colonoscopy. This research should mean that patients with bowel cancer symptoms can get the best test for them.”
Sara Hiom, Cancer Research UK’s director of early diagnosis, said: “Survival rates for bowel cancer have doubled over the last 40 years thanks to better treatments and improved ways of diagnosing the disease. This research will mean that anyone with a suspected bowel cancer has two effective options to further investigate their symptoms.”
For media enquiries please contact the Cancer Research UK press office on 020 3469 8300 or, out-of-hours, the duty press officer on 07050 264 059.
2. Halligan, S. Computed tomographic colonography versus double contrast barium enema for diagnosis of colorectal cancer or large polyps in symptomatic patients: a multicentre randomised trial in clinical practice Lancet (2013)
3. Atkin, W.S. et al Computed tomographic colonography versus colonoscopy for investigation of patients with symptoms of colorectal cancer: a multicentre randomised trial in clinical practice Lancet (2013)
Notes to editors
1. The research was funded by the NIHR, Cancer Research UK, and the EPSRC.
About the NIHR
- The National Institute for Health Research Health Technology Assessment (NIHR HTA) Programme funds research about the effectiveness, costs, and broader impact of health technologies for those who use, manage and provide care in the NHS. It is the largest NIHR programme and publishes the results of its research in the Health Technology Assessment journal, with over 600 issues published to date. The journal’s 2011 Impact Factor (4.255) ranked it in the top 10% of medical and health-related journals. All issues are available for download, free of charge, from the website. The HTA Programme is funded by the NIHR, with contributions from the CSO in Scotland, NISCHR in Wales, and the HSC R&D Division, Public Health Agency in Northern Ireland.www.hta.ac.uk.
- The National Institute for Health Research (NIHR) is funded by the Department of Health to improve the health and wealth of the nation through research. Since its establishment in April 2006, the NIHR has transformed research in the NHS. It has increased the volume of applied health research for the benefit of patients and the public, driven faster translation of basic science discoveries into tangible benefits for patients and the economy, and developed and supported the people who conduct and contribute to applied health research. The NIHR plays a key role in the Government’s strategy for economic growth, attracting investment by the life-sciences industries through its world-class infrastructure for health research. Together, the NIHR people, programmes, centres of excellence and systems represent the most integrated health research system in the world. For further information, visit the NIHR website (www.nihr.ac.uk).